Lactoferrin for Helicobacter Pylori
Verdict: Published with Warning
Across 4 PubMed studies, the evidence for Lactoferrin in Helicobacter Pylori grades Tier B — preliminary evidence. Effective, but with safety or population caveats.
B 🟡 B Preliminary Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.63
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
78%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.625
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高階證據未達主導 (0 positive vs 1 negative)，由 raw_score 決定
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (4)L2 · primary research & systematic reviews
Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy
Finding: Adding lactoferrin raised ITT eradication from 74.44% to 86.57% (OR 2.26, 95% CI 1.70-3.00) and lowered total adverse events from 16.28% to 9.05%, driven by less nausea (OR 0.15, 95% CI 0.04-0.54).
View on PubMed Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication
Finding: Five RCTs (n=682; LF 316 vs control 366) gave a pooled ITT eradication OR of 2.22 (95% CI 1.44-3.44, P=0.0003; risk difference +0.11, 95% CI 0.05-0.16) with NO significant difference in adverse effects, and the authors explicitly call the evidence limited.
View on PubMed Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study
Finding: Triple therapy plus CONCURRENT lactoferrin achieved 90% eradication vs 77% for triple therapy alone and only 73% when lactoferrin was given as 7-day pretreatment before triple therapy (chi-square P<0.01); adverse events were similar across arms (~8-9.5%, P=0.1).
View on PubMed Efficacy of Lactoferrin with Standard Triple Therapy or Sequential Therapy for Helicobacter pylori Eradication: A Randomized Controlled Trial
Finding: Lactoferrin add-on raised per-protocol eradication for triple therapy (85.6% vs 70.3%, P=.014) and for sequential therapy (94.5% vs 82.8%, P=.013), with no severe adverse reactions and minor side effects causing discontinuation in 3.3%.
View on PubMed